Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 114,400,904
  • Shares Outstanding, K 2,521,510
  • Annual Sales, $ 38,408 M
  • Annual Income, $ 4,864 M
  • 36-Month Beta 0.88
  • Price/Sales 3.02
  • Price/Cash Flow 9.70
  • Price/Book 1.78

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.32 +2.37%
on 11/20/17
49.72 -8.74%
on 10/23/17
-4.14 (-8.36%)
since 10/20/17
3-Month
44.32 +2.37%
on 11/20/17
50.65 -10.42%
on 09/22/17
-3.09 (-6.38%)
since 08/22/17
52-Week
38.45 +18.00%
on 12/16/16
50.65 -10.42%
on 09/22/17
+5.51 (+13.82%)
since 11/22/16

Most Recent Stories

More News
Alnylam's RNAi Candidate Gains Breakthrough Therapy Status

Alnylam (ALNY) announced that the FDA has granted Breakthrough Therapy Designation for RNAi therapeutic candidate, patisiran.

LGND : 133.06 (+2.33%)
SCMP : 10.40 (+0.48%)
ALNY : 132.33 (+0.24%)
SNY : 45.37 (+1.29%)
Alnylam Starts Rolling NDA Submission for RNAi Candidate

Alnylam (ALNY) has started rolling New Drug Application to the FDA for its RNAi candidate, patisiran.

CORT : 17.75 (+0.97%)
LGND : 133.06 (+2.33%)
ALNY : 132.33 (+0.24%)
SNY : 45.37 (+1.29%)
Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?

Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.

ALNY : 132.33 (+0.24%)
NVS : 84.48 (+0.24%)
RHHBY : 31.6600 (+1.90%)
SNY : 45.37 (+1.29%)
Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA

Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.

CORT : 17.75 (+0.97%)
LGND : 133.06 (+2.33%)
ALNY : 132.33 (+0.24%)
SNY : 45.37 (+1.29%)
Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day

Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.

AZN : 33.83 (+0.30%)
NVO : 51.84 (+0.17%)
MRK : 54.37 (+0.18%)
LLY : 83.68 (+0.20%)
PFE : 35.43 (-0.31%)
SNY : 45.37 (+1.29%)
Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y

Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.

JNJ : 137.29 (-0.76%)
IPXL : 16.95 (+0.59%)
NVS : 84.48 (+0.24%)
SNY : 45.37 (+1.29%)
Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.

AZN : 33.83 (+0.30%)
JNJ : 137.29 (-0.76%)
MRK : 54.37 (+0.18%)
LLY : 83.68 (+0.20%)
RHHBY : 31.6600 (+1.90%)
GSK : 35.06 (+0.72%)
SNY : 45.37 (+1.29%)
Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.

BAYRY : 32.0500 (-0.47%)
EXEL : 26.13 (+0.31%)
REGN : 387.54 (+0.81%)
SNY : 45.37 (+1.29%)
Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates

Alnylam Pharmaceuticals (ALNY) incurred wider than expected loss and missed sales estimates in the third quarter of 2017.

LGND : 133.06 (+2.33%)
MDCO : 31.40 (+0.71%)
ALNY : 132.33 (+0.24%)
SNY : 45.37 (+1.29%)
Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised

Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.

APVO : 3.06 (+5.88%)
EBS : 40.87 (+3.94%)
GSK : 35.06 (+0.72%)
SNY : 45.37 (+1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

2nd Resistance Point 45.88
1st Resistance Point 45.63
Last Price 45.37
1st Support Level 45.12
2nd Support Level 44.86

See More

52-Week High 50.65
Fibonacci 61.8% 45.99
Last Price 45.37
Fibonacci 50% 44.55
Fibonacci 38.2% 43.11
52-Week Low 38.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart